All Ranbaxy articles
-
BusinessFormer Ranbaxy owners arrested for fraud
Singh brothers accused of misappropriation, as well as not paying previous fines relating to Ranbaxy’s takeover by Daiichi Sankyo
-
BusinessIndian court seizes former Ranbaxy owners’ assets
Daiichi Sankyo inches closer to recovering money from Singh brothers
-
BusinessIndia hit hard by US regulatory sanctions
Data integrity issues have led to punitive measures, but companies are taking measures to improve
-
BusinessDaiichi Sankyo awarded damages from former Ranbaxy owners
Arbitration says Singh family withheld information about regulatory investigations during Ranbaxy takeover
-
BusinessIndian whistleblower pushes for regulatory reform
Although denied a hearing by India’s supreme court, Dinesh Thakur wants to shake up pharmaceutical safety laws
-
BusinessIndian pharma under increased regulatory scrutiny
Import bans and tightened rules pose a significant challenge for companies
-
Business
Daiichi Sankyo steps out after Sun-Ranbaxy merger
Ranbaxy’s Japanese owner has sold off its stake in the merged company, but will retain its business partnership
-
Business
Sun Pharma snares Ranbaxy in $4bn deal
Acquisition makes Sun biggest drug firm in India and fifth largest generics producer in the world
-
Business
Teva wins generic esomeprazole race
US approval of heartburn drug after Ranbaxy version was withdrawn by regulators
-
-
Business
Ranbaxy sues over withdrawn US approvals
Company says decision is ‘unconstitutional’ and deprives it of hundreds of millions of dollars in revenue
-
Business
Insider trading allegations stall Sun–Ranbaxy deal
Companies deny wrongdoing in lead-up to merger announcement
-
BusinessSun set on Ranbaxy rescue
Acquiring beleaguered firm will create India’s biggest pharmaceutical company
-
Business
US blocks imports from fourth Ranbaxy plant
FDA bans import of active ingredients from factory in Toansa, India
-
-
FeatureGeneric problems
The Indian pharmaceutical industry has been hit by recent problems. Angeli Mehta investigates
-
BusinessPharma manufacturing woes dog industry
Regulators are stepping up inspections, and discovering ever more problems
-
Business
$500m fine over generics fraud for Ranbaxy
Company has pleaded guilty to fabricating data and producing substandard drugs
-
Business2012 pharma industry roundup
What were the bigger stories? And how did the industry fare overall?
-
Business
Generic Actos approved
Mylan, Ranbaxy and Teva have won US marketing approval for their generic versions of Actos diabetes tablets